BANDERA, ALESSANDRA
 Distribuzione geografica
Continente #
NA - Nord America 3.893
AS - Asia 2.368
EU - Europa 1.882
SA - Sud America 400
AF - Africa 52
Continente sconosciuto - Info sul continente non disponibili 7
OC - Oceania 5
Totale 8.607
Nazione #
US - Stati Uniti d'America 3.766
SG - Singapore 813
CN - Cina 602
RU - Federazione Russa 367
HK - Hong Kong 354
VN - Vietnam 334
BR - Brasile 331
DE - Germania 274
IT - Italia 263
IE - Irlanda 258
SE - Svezia 244
GB - Regno Unito 105
UA - Ucraina 105
CA - Canada 89
FI - Finlandia 57
DK - Danimarca 54
IN - India 50
AR - Argentina 36
ID - Indonesia 33
FR - Francia 32
ZA - Sudafrica 30
TR - Turchia 28
KR - Corea 27
BD - Bangladesh 24
AT - Austria 23
NL - Olanda 23
JP - Giappone 22
PL - Polonia 19
IQ - Iraq 17
MX - Messico 17
ES - Italia 15
BE - Belgio 13
IR - Iran 9
EC - Ecuador 8
SA - Arabia Saudita 8
HN - Honduras 6
LT - Lituania 6
MA - Marocco 6
AE - Emirati Arabi Uniti 5
CO - Colombia 5
EU - Europa 5
KE - Kenya 5
UZ - Uzbekistan 5
AU - Australia 4
AZ - Azerbaigian 4
BZ - Belize 4
CL - Cile 4
CR - Costa Rica 4
CZ - Repubblica Ceca 4
EG - Egitto 4
JO - Giordania 4
NP - Nepal 4
PK - Pakistan 4
PY - Paraguay 4
UY - Uruguay 4
CH - Svizzera 3
DO - Repubblica Dominicana 3
IL - Israele 3
MY - Malesia 3
PE - Perù 3
PT - Portogallo 3
TW - Taiwan 3
VE - Venezuela 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AL - Albania 2
BO - Bolivia 2
KH - Cambogia 2
LB - Libano 2
LV - Lettonia 2
ML - Mali 2
MN - Mongolia 2
PH - Filippine 2
RO - Romania 2
SC - Seychelles 2
SI - Slovenia 2
BB - Barbados 1
BG - Bulgaria 1
BH - Bahrain 1
BS - Bahamas 1
BY - Bielorussia 1
EE - Estonia 1
GR - Grecia 1
JM - Giamaica 1
LK - Sri Lanka 1
LU - Lussemburgo 1
MD - Moldavia 1
NG - Nigeria 1
NZ - Nuova Zelanda 1
OM - Oman 1
PR - Porto Rico 1
SN - Senegal 1
TH - Thailandia 1
TN - Tunisia 1
Totale 8.607
Città #
Singapore 502
Ann Arbor 375
Ashburn 352
Hong Kong 351
Fairfield 276
Chandler 271
Dublin 253
Houston 188
Woodbridge 186
Wilmington 174
Frankfurt am Main 168
New York 145
Dallas 134
Ho Chi Minh City 111
Los Angeles 106
Seattle 102
Jacksonville 100
Dearborn 96
Beijing 94
Cambridge 94
Milan 84
Hanoi 82
Princeton 71
Santa Clara 67
Hefei 65
Shanghai 50
Buffalo 43
Nanjing 41
The Dalles 35
Lawrence 32
São Paulo 32
Altamura 31
Moscow 30
Ottawa 28
Munich 27
Helsinki 26
Chicago 24
Seoul 24
Fremont 21
Tokyo 21
Florence 20
Kent 20
Nanchang 20
San Diego 20
Jakarta 19
Lachine 19
Dong Ket 18
Denver 17
Nuremberg 17
Rio de Janeiro 17
Toronto 17
Hangzhou 16
London 16
Brussels 13
Guangzhou 13
Salt Lake City 13
Andover 12
Edmonton 12
Shenyang 12
Vienna 12
Brooklyn 11
Columbus 11
Redondo Beach 11
Amsterdam 10
Brasília 10
Changsha 10
Durban 10
Hebei 10
Kunming 10
Quận Bình Thạnh 9
Warsaw 9
Boardman 8
Buenos Aires 8
Da Nang 8
Ha Long 8
Johannesburg 8
Kiev 8
Norwalk 8
Orem 8
Pune 8
Tianjin 8
Boston 7
Chennai 7
Falls Church 7
Jinan 7
Montreal 7
Poplar 7
San Francisco 7
Zhengzhou 7
Belo Horizonte 6
Council Bluffs 6
Elk Grove Village 6
Miami 6
Romola 6
Turku 6
Atlanta 5
Baghdad 5
Biên Hòa 5
Bắc Giang 5
Can Tho 5
Totale 5.543
Nome #
Similar success rates but lower incidence of telaprevir-related rash in HIV/HCV coinfected as compared to HCV-monoinfected patients treated with triple anti-HCV therapy 303
Microbiota in ICU, not only a gut problem 299
Effects of autologous stem cell transplantation in HIV: searching for the origins of viral replication in settings of profound CD4(+) T cell depletion 284
Brief Report: Peripheral Monocyte/Macrophage Phenotypes Associated with the Evolution of Cognitive Performance in HIV-Infected Patients 274
A case of cerebrospinal fluid viral escape on a dual antiretroviral regimen: Worth the risk? 265
Impact of orotracheal intubation and mechanical ventilation on the microbiota of the lung in the development of Ventilator- Associated Pneumonia 263
Prospective immune dynamics during the first 24 weeks of efavirenz based-antiretroviral therapy in HIV-1-infected subjects, according to CD4+ T-cell counts at presentation: The IMMUNEF clinical trial 260
Triglyceride/HDL ratio and its impact on the risk of diabetes mellitus development during ART 256
Durability of different initial regimens in HIV-infected patients starting antiretroviral therapy with CD4+ counts <200 cells/mm3 and HIV-RNA >5 log10 copies/mL 254
Brachial and central blood pressure in HIV-infected subjects 254
Strategies to limit immune-activation in HIV patients 238
Evaluation of adhesion molecules and immune parameters in HIV-infected patients treated with an atazanavir/ritonavir- compared with a lopinavir/ritonavir-based regimen 232
ECMO: An alternative support for acute respiratory failure caused by tuberculosis? 231
A case of classic neuromyelitis optica (Devic's syndrome) triggered by pegylated-interferon α 229
Customization of LC-MS-based proteomic workflows for biological studies in the clinical field 219
Specific prebiotics modulate gut microbiota and immune activation in HAART-naive HIV-infected adults: Results of the "cOPA" pilot randomized trial 215
Unmasking tuberculosis in the era of antiretroviral treatment 212
Combination antifungal therapy for invasive mold infections among pediatric patients with hematological malignancies: Data from a real-life case-series 211
Lung cryptococcosis in a treated HIV-1-infected patient with suppressed viral load and past disseminated cryptococcosis: Relapse or late IRIS? 209
KIR-HLA genotypes in HIV-infected patients lacking immunological recovery despite effective antiretroviral therapy 208
Use of CXCR4-antagonist for haematopoietic stem cell mobilization in HIV-infected patients with haematological malignancies 204
Changes in subcutaneous adipose tissue microRNA expression in HIV-infected patients 201
Plasma Proteomic Variables Related to COVID-19 Severity: An Untargeted nLC-MS/MS Investigation 199
Untargeted mass spectrometry approach to study SARS-CoV-2 proteins and characterize human plasma and saliva proteome in COVID-19 patients. 188
Characterization of immune failure by monocyte activation phenotypes in HIV-infected patients receiving antiretroviral therapy 177
Under representation of the inhibitory KIR3DL1 molecule and the KIR3DL1+/BW4+ complex in HIV exposed seronegative individuals 174
Impact of dexamethasone on the incidence of ventilator-associated pneumonia in mechanically ventilated COVID-19 patients: a propensity-matched cohort study 174
High-density lipoprotein-cholesterol levels and risk of cancer in HIV-infected subjects Data from the ICONA Foundation Cohort 168
Immunosuppressant Treatment in Rheumatic Musculoskeletal Diseases Does Not Inhibit Elicitation of Humoral Response to SARS-CoV-2 Infection and Preserves Effector Immune Cell Populations 167
Plasma proteome investigation of COVID-19 patients with different outcomes through an untargeted label-free LC-MS/MS approach. 164
SARS-CoV-2 RNA in plasma samples of COVID-19 affected individuals: a cross-sectional proof-of-concept study 154
Exogenous reinfection of tuberculosis in a low-burden area 147
Early changes in adhesion molecules expression and endothelial function in patients initiating ART with Atazanavir or Lopinavir 143
Predictors of COVID-19 Readmission Among Patients Previously Hospitalized for SARS-CoV-2 141
HIV-DNA decrease during treatment in primary HIV-1 infection with three different drug regimens: Italian Network of Acute HIV Infection (INACTION) clinical trial 140
Plasma proteomic signatures related to COVID-19 disease severity by an untargeted nLC-ESI-MS/MS approach 137
Evaluation of HIV transmission clusters among natives and foreigners living in Italy 133
Arterial structural and functional effects of two different antiretroviral therapy protocol on naïve HIV-infected subjects 131
Unmasked tuberculosis or lymphoma in late AIDS presenters: A difficult differential diagnosis 127
Corrigendum: The Impact of Anti-rheumatic Drugs on the Seroprevalence of Anti-SARS-CoV-2 Antibodies in a Cohort of Patients With Inflammatory Arthritis: The MAINSTREAM Study(Front. Med., (2022), 9, (850858), 10.3389/fmed.2022.850858) 127
Risk for non-AIDS-defining and AIDS-defining cancer of early versus delayed initiation of antiretroviral therapy: A multinational prospective cohort study 126
Characterization of SARS-CoV-2 proteins and human proteome in COVID-19 patients’ saliva and plasma: an untargeted mass spectrometry approach 124
Plasma, Intracellular and Lymph Node Antiretroviral Concentrations and HIV DNA Change During Primary HIV Infection: Results from the INACTION P25 Study 117
First-line antiretroviral therapy with efavirenz plus tenofovir disiproxil fumarate/emtricitabine or rilpivirine plus tenofovir disiproxil fumarate/emtricitabine: a durability comparison 117
3-Year efficacy and durability of simplification to single tablet regimens: a comparison between co-formulated efavirenz/emtricitabine/tenofovir and rilpivirine/emtricitabine/tenofovir 114
Is physician assessment of alcohol consumption useful in predicting risk of severe liver disease among people with HIV and HIV/HCV co-infection? 103
Prognostic Value of the Fibrosis-4 Index in Human Immunodeficiency Virus Type-1 Infected Patients Initiating Antiretroviral Therapy with or without Hepatitis C Virus 103
Switching to dual/monotherapy determines an increase in CD8+ in HIV-infected individuals: An observational cohort study 102
Occupational HIV infection in a research laboratory with unknown mode of transmission: a case report 3
Totale 9.021
Categoria #
all - tutte 32.189
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 32.189


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021288 0 0 0 0 0 49 40 55 47 37 21 39
2021/2022474 15 21 46 60 20 48 21 36 23 55 29 100
2022/2023959 102 316 74 113 40 129 10 68 65 8 23 11
2023/2024754 19 14 46 32 92 217 144 37 52 23 6 72
2024/20251.813 88 181 125 90 147 78 131 38 206 318 155 256
2025/20262.502 675 331 438 467 537 54 0 0 0 0 0 0
Totale 9.021